Orchid Pharma Q2 EBITDA margin reaches 15% as profit rises
Key highlights
- Orchid Pharma reported Q2 FY27 standalone EBITDA of Rs 52 crore, up 148% from Rs 20 crore in Q2 FY26.
- Orchid Pharma’s standalone EBITDA margin rose to 15% in Q2 FY27 from 7% a year earlier.
- Orchid Pharma’s Q2 FY27 standalone profit for the period was Rs 36.76 crore, compared with Rs 6.91 crore in Q2 FY26.
- Orchid Pharma’s H1 FY27 standalone revenue from operations increased 15% to Rs 645.44 crore.
powered by IRIS

Orchid Pharma Ltd. reported a 15% standalone earnings before interest, tax, depreciation and amortisation (EBITDA) margin in the second quarter of financial year 2027 (Q2 FY27), up from 7% a year earlier, as revenue from operations rose 14% to Rs 341.27 crore and profit for the period reached Rs 36.76 crore.
Know Orchid Pharma inside out
Results, valuation, peers and who's buying, in one view.
How did Orchid Pharma’s standalone Q2 FY27 earnings change?
Orchid Pharma reported standalone revenue from operations of Rs 341.27 crore for the quarter ended September 2026, compared with Rs 298.46 crore in the quarter ended September 2025. Total income, which includes other income, rose to Rs 369.90 crore from Rs 314.75 crore. Other income increased to Rs 28.63 crore from Rs 16.29 crore, while revenue from operations contributed Rs 42.81 crore of the Rs 55.15 crore increase in total income.
Standalone EBITDA was Rs 52 crore in Q2 FY27, compared with Rs 20 crore in Q2 FY26, a 148% increase in Orchid Pharma’s quarterly performance summary. The corresponding EBITDA margin increased by 8 percentage points to 15% from 7%. The presentation also reports gross margin of Rs 133 crore, compared with Rs 92 crore a year earlier, an increase of Rs 41 crore.
Profit before exceptional items and tax reached Rs 36.76 crore in Q2 FY27, versus Rs 6.91 crore in Q2 FY26. Orchid Pharma reported no exceptional items and no tax expense in either standalone quarter, so profit before tax and profit for the period were both Rs 36.76 crore in Q2 FY27. Basic and diluted earnings per share rose to Rs 6.14 from Rs 1.15.
What drove the difference between revenue growth and profit growth?
Orchid Pharma’s revenue grew by 14%, but standalone EBITDA increased by 148% and profit for the period increased by Rs 29.85 crore. The disclosed cost lines show cost of materials consumed rising to Rs 245.96 crore from Rs 172.05 crore, while changes in inventories became a negative Rs 38.95 crore expense compared with a Rs 34.79 crore expense in Q2 FY26. These two lines, along with purchases of stock-in-trade, are reflected in the presentation’s summary cost of goods sold of Rs 208 crore in Q2 FY27 versus Rs 207 crore a year earlier.
Employee benefits expense increased to Rs 32.69 crore from Rs 30.64 crore, and other expenses rose to Rs 77.04 crore from Rs 56.92 crore. Finance costs were Rs 3.66 crore, compared with Rs 2.57 crore, while depreciation and amortisation were Rs 11.32 crore, compared with Rs 10.70 crore. Total standalone expenses increased to Rs 333.14 crore from Rs 307.84 crore, a rise of Rs 25.30 crore that was smaller than the Rs 55.15 crore increase in total income.
The quarterly improvement also followed a lower first quarter. Revenue from operations increased by Rs 37.10 crore from Rs 304.17 crore in Q1 FY27 to Rs 341.27 crore in Q2 FY27. Profit for the period increased to Rs 36.76 crore from Rs 11.94 crore over the same sequential comparison, while total income rose to Rs 369.90 crore from Rs 314.22 crore.
Got a follow-up? Ask IRIS
How has Orchid Pharma performed in the first half of FY27?
Orchid Pharma reported standalone revenue from operations of Rs 645.44 crore in H1 FY27, compared with Rs 561.64 crore in H1 FY26, a 15% increase. The company’s H1 FY27 total income was Rs 684.12 crore, up from Rs 593.99 crore. EBITDA rose to Rs 77 crore from Rs 31 crore, and EBITDA margin increased to 12% from 5% in Orchid Pharma’s half-year performance summary.
Standalone profit for the period reached Rs 48.70 crore in H1 FY27, compared with Rs 4.50 crore in H1 FY26. Profit before exceptional items and tax was also Rs 48.70 crore, as neither half-year carried an exceptional items or standalone tax expense. H1 basic and diluted earnings per share were Rs 8.13, compared with Rs 0.75 in the prior-year half.
The first-half trend shows that Q2 accounted for Rs 36.76 crore of H1 FY27 profit, following Rs 11.94 crore in Q1 FY27. H1 gross margin was Rs 232 crore, compared with Rs 171 crore in H1 FY26. Revenue growth was 15% over the half year, while reported EBITDA growth was 151%, showing that the margin change was present over both the quarter and six-month period.
How do Orchid Pharma’s standalone results compare with consolidated results?
Orchid Pharma’s consolidated revenue from operations was identical to standalone revenue at Rs 341.27 crore in Q2 FY27, but consolidated total income was lower at Rs 359.02 crore because consolidated other income was Rs 17.76 crore, versus Rs 28.63 crore on a standalone basis. Consolidated profit for the period was Rs 28.59 crore, compared with standalone profit of Rs 36.76 crore.
The consolidated result included a Rs 1.71 crore share of profit from associates and joint ventures, compared with a Rs 2.39 crore share of loss in Q2 FY26. Consolidated profit before tax was Rs 26.84 crore, compared with Rs 1.34 crore a year earlier, and consolidated basic and diluted earnings per share were Rs 4.77, compared with a loss per share of Rs 0.15.
At September 30, 2026, consolidated total assets were Rs 2,652.35 crore, compared with Rs 2,258.43 crore at March 31, 2026. Consolidated gross borrowings rose to Rs 543.66 crore from Rs 301.44 crore, while net debt increased to Rs 487 crore from Rs 218 crore. Orchid Pharma attributed a Rs 368 crore increase in non-current assets partly to capital work-in-progress on the 7ACA and Cefiderocol projects, funded partly by incremental borrowings.
Conclusion
Orchid Pharma’s Q2 FY27 standalone results show a sharper increase in earnings than in revenue: revenue from operations rose 14% to Rs 341.27 crore, EBITDA rose 148% to Rs 52 crore, and margin rose to 15% from 7%. Profit for the period increased to Rs 36.76 crore from Rs 6.91 crore, while H1 FY27 profit reached Rs 48.70 crore from Rs 4.50 crore.
The next reported results will show whether the 15% Q2 EBITDA margin is sustained as Orchid Pharma continues work on the 7ACA and Cefiderocol projects. The disclosed balance-sheet position makes the related funding a measurable item: consolidated net debt was Rs 487 crore and debt to equity was 0.33 times at September 30, 2026, compared with Rs 218 crore and 0.19 times at March 31, 2026.


